Visit https://www.peervoice.com/RKE860 to view the entire programme with slides. After completing “Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses”, participants will be able to: Summarise the most recent clinical data for radioligand therapy (RLT) for the management of men with metastatic castration-resistant prostate cancer (mCRPC); Evaluate how these data add to previous knowledge about the management of mCRPC with RLT; and Discuss the clinical implications of these data in the context of current treatment paradigms for mCRPC.

Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/NYE860 to view the entire programme with slides. After completing “Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy”, participants will be able to: Assess current treatment options for first-line management of advanced urothelial carcinoma (aUC), including maintenance therapy; Identify patients with aUC who may benefit from maintenance therapy; Formulate appropriate maintenance therapy plans for patients with aUC; and Identify emerging therapies, including maintenance therapies, for the management of aUC.

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Visit https://www.peervoice.com/UGT860 to view the entire programme with slides. After completing “Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer ”, participants will be able to: Assess the clinical relevance of randomised controlled trial (RCT) data evaluating the safety and efficacy of TROP2-directed therapies in the management of HR+/HER2- advanced breast cancer; and Identify patients with HR+/HER2- advanced breast cancer who may benefit from treatment with a TROP2-directed therapy.

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Visit https://www.peervoice.com/GYE860 to view the entire programme with slides. After completing “Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics”, participants will be able to: Assess available safety and efficacy data from randomised clinical trials evaluating first- and next-generation FLT3 inhibitors in acute myeloid leukaemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilising recommended dose schedules; and Formulate adverse event management strategies for patients with newly diagnosed FLT3-mutant AML receiving a FLT3 inhibitor, including monitoring and supportive treatment.

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Visit https://www.peervoice.com/YZV860 to view the entire programme with slides. After completing “Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?”, participants will be able to: Identify risk factors associated with toxicity development in patients with squamous cell carcinoma of the head and neck (SCCHN) who are undergoing chemoradiotherapy (CRT); Use patient and disease characteristics to determine pre-emptive approaches to reducing toxicity risk in patients with SCCHN who are to receive CRT; and Apply current recommendations for the management of CRT-associated toxicities in patients with SCCHN.

Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?

Visit https://www.peervoice.com/JEG860 to view the entire programme with slides. After completing “Ali Aamer Habib, MD - Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis”, participants will be able to: Describe the limitations of current targeted immunotherapies for patients with generalised myasthenia gravis (gMG); Identify emerging targeted therapies for gMG; and Explain how emerging targeted therapies for gMG differentiate from other therapies within the same class.

Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Download our free app to listen on your phone